Skip to content

Raloxifene in men with chronic schizophrenia

raloxifene as an add-on therapy in men with chronic schizophrenia: a randomized double blind and placebo controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201211211556N47
Enrollment
46
Registered
2012-11-24
Start date
2012-11-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. schizophrenia

Interventions

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:1-Diagnosis of Schizophrenia based on DSM- IV criteria;2- Minimum Score of 60 on Positive and Negative Scale 3- Age between 18-55;4-male sex 5- chronic Schizophrenia- duration of the disorder more than 2 years; ; 6-Minimum score of 20 in negative suscore Exclusion Criteria:1-any other mental disorder on axis I; 2-Any serious medical or neurological problem; 3- IQ less than 70;4- Substance dependence during the last 6 months(except for nicotine and caffeine) 5-receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month; ;6-receiving ECT during the last 14 days, 7-Endocrine abnormality; 8-hepatic and renal disease 9- history of thrombosis and embolism 10 history of abnormal bleeding 11- CVA

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026